PDTs, biosimilars hot topics at AMCP meeting | AMCP 2023
The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for prescription digital therapeutics.
Prescription digital therapeutics (PDTs) and biosimilars were on the top of the agenda of the annual meeting of the Academy of Managed Care Pharmacy (AMCP) last week in San Antonio. Several speakers commented on the energy of the meeting, which had an attendance of just over 3,500.
“This place is just buzzing,” said Deb Curry, the past president of AMCP, before broadcaster Robin Roberts spoke at the general on session on Wednesday.
AMCP is lobbying for passage of the Access to Prescription Digital Therapeutics Act, which would create a new benefit category for PDTs. During a session on federal legislation and regulation, Jenifer L. Mathieu, the organization’s senior vice president, professional and government affairs, discussed the bill’s prospects. On the one hand, Mathieu said the bill has the advantage of bipartisan sponsorship in both the Senate and House in a closely divided Congress that makes legislation with bipartisan support political attractive and feasible. On the other hand, Mathieu stressed how long legislation takes to get through Congress, and the Congressional Budget Office has yet to assess (“score”) its effect on the federal spending, a key step in the legislative process.
The meeting also featured a session on how health plans are going about deciding to whether to cover PDTs. The panelists — Joseph Albright of BlueCross BlueShield of North Carolina, Terry Cothran of the Oklahoma Health Care Authority, and Sam Sui of Fallon Health — discussed adding subject matter expertise to the pharmacy and therapeutics (P&T) committee process but also said it was too soon to start hiring additional people to review PDTs.
In addition, the exhibition hall had prescription digital therapeutics pavilion PDT companies showed off their wares.
New this year was a biosimilar track comprising four sessions. Outside of those sessions, biosimilars came up often, a reflection of their growing market share and the launching of biosimilars to Humira (adalimumab) this year. In his keynote presentation, Douglas Long of IQVIA and a regular speaker at AMCP and other conferences, showed figures that project spending on biosimilar will more than triple from $11.4 billion this to $38.5 billion in 2027.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
April 18th 2024Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More
